Summary
• Corcept Therapeutics shares fell 36% in pre-market trading after receiving a complete response letter from the FDA for relacorilant.
• The company’s earnings per share of $0.16 missed expectations of $0.18, causing further investor concern.
• Analysts still hold a “Buy” rating on the stock, indicating potential long-term favorability despite the recent volatility.
Corcept Therapeutics Incorporated (CORT) is experiencing a sharp decline in pre-market trading, with shares down 36% to $44.60 from the last close of $70.19. This significant drop comes after the company received a complete response letter from the FDA regarding its application for relacorilant, a treatment for patients with hypercortisolism.
Regulatory Setback Affects Investor Sentiment
The recent news from Corcept has raised concerns among investors. The complete response letter indicates that the FDA has not approved the new drug application for relacorilant at this time, which could delay potential revenue streams and impact the company’s market positioning. Corcept specializes in medications that target disorders related to cortisol modulation, and this setback places a shadow over its future earnings prospects.
Financially, Corcept reported a current actual earnings per share of $0.16, slightly below the expected $0.18, highlighting a surprising deviation of over 11%. Comparatively, in the previous quarter, the company exceeded estimates, which adds to the disappointment surrounding this latest response from regulators.
Market and Technical Picture
Corcept’s market performance has shown notable volatility. The average trading volume over the last 10 days stands at approximately 1,009,932 shares, aligning with a recent volume of 277,850, suggesting heightened activity amid the pre-market decline. Over the past year, the stock has seen a more than 37% increase, but recent metrics reveal a difficult landscape with a quarterly performance down by 16.34%. Currently, the Relative Strength Index (RSI) sits at 32.16, indicating that the stock could be approaching oversold conditions.
Analyst Sentiment
Despite the recent downturn, analysts maintain a “Buy” rating on Corcept shares. This suggests that, while the immediate sentiment is reactive to the FDA’s decision, long-term prospects might still be viewed favorably by some in the market. The shift in earnings expectations and market fluctuations will be critical metrics for stakeholders to monitor as the company navigates this setback.
With the stock reacting sharply to the FDA’s news, investors will be closely watching how sentiment evolves and what potential steps Corcept may take in addressing the regulatory challenges ahead.